Anabolic agents for osteoporosis not clearly better than zoledronic acid: ICER analysis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • The Institute for Clinical and Economic Review (ICER) found no evidence that either abaloparatide (Tymlos) or teriparatide (Forteo) had superior efficacy vs the other or vs zoledronic acid in preventing postmenopausal vertebral fracture.

Why this matters

  • Patients’ adh...